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Abstract
Background Acute lymphoblastic leukemia (ALL) is a neoplastic 
disease resulting from somatic mutation in the lymphoid progenitor 
cells, often occuring in children aged 2-5 years, predominantly 
in males. Results from the induction phase of chemtherapy are 
used to measure success, but the failure remission rate is still 
high. Increased apoptosis of cancer cells, as induced by CD4+ 
and CD8+ T-cells, is an indicator of prognosis and response to 
chemotherapy. 
Objective To assess for correlations between CD4+, CD8+, or 
CD4+/CD8+ ratio to the chemotherapy induction phase response 
(i.e., apoptosis) in pediatric ALL patients.
Methods This observational analytical cohort study was done 
in 25 pediatric ALL patients. Whole blood (3 mL) with EDTA 
anticoagulant were used to measure absolute counts of CD4+, 
CD8+, and CD4+/CD8+ ratio. Peripheral blood mononuclear cells 
(PBMC) were examined for apoptosis. The principle of CD4+, 
CD8+ examination was bond between antigens on the surface of 
the leukocyte in the blood with fluorochrome labeled antibodies 
in the reagents, while the principle of apoptosis examination 
was FITC Annexin V will bonds with phosphatidylserine that 
moves out of the cell when the cell undergoes apoptosis, then 
intercalation with propidium iodide (PI). All examination were 
detected by flow cytometry BD FACSCalibur.
Results Subjects were 25 newly-diagnosed, pediatric ALL patients 
(64% males and 36% females). Most subjects were 3 years of age 
(20%). Numbers of CD4+ and CD8+ cells, as well as CD4+/
CD8+ ratio were significantly decreased after chemotherapy. 
However, apoptosis was not significantly different before and 
after chemotherapy (P=0.689), There were significant negative 
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correlations between apoptosis and CD4+ (P=0.002; rs=-0.584), 
and CD8+ (rs=-0.556; P=0.004), before chemotherapy. In 
addition, CD4+-delta and apoptosis-delta also had a significant 
positive correlation (rs=0.478; P=0.016). However, no correlation 
was found between the CD4+/CD8+ ratio and apoptosis, before 
or after chemotherapy. 
Conclusion There are significantly lower mean CD4+, CD8+, 
and CD4+/CD8+ ratio after chemotherapy than before. Also, 
there are significant correlations between CD4+-delta and 
apoptosis-delta, as well as between apoptosis and CD4+, CD8+, 
and CD4+/CD8+ ratio, before chemotherapy. The CD4+, CD8+, 
and CD4+/CD8+ ratio can be used to predict apoptosis before 
chemotherapy. In addition, CD4+-delta can be used to predict 
apoptosis-delta as a response to induction phase chemotherapy in 
pediatric ALL. [Paediatr Indones. 2017;57:138-43 doi: http://
dx.doi.org/10.14238/pi57.3.2017.138-43  ].
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Acute lymphoblastic leukemia (ALL) is a neoplastic disease resulting from somatic mutation in the lymphoid progenitor cells in the bone marrow, often occurring 
in children aged 2-5 years, and predominantly in 
males. Diagnosis of ALL is based on finding ≥ 
25% lymphoblasts of blood smear or bone marrow 
aspiration (BMA) evaluation.  Outcome criteria was 
made as follows, < 5% lymphoblasts was belonging to 
remission, and > 5% was belonging to non remission, 
including partial remission.1-5 
Failure of apoptosis and the immune response 
causes uncontrolled growth of cancer cells. The 
progression of ALL has been correlated with 
quantitative and qualitative (function) host immune 
responses. Cluster differentiation 8+ (CD8+) T-cell 
are an effector cell resulting an apoptosis tumor 
cells by cytotoxic or cytolytic effects. Anti-tumor 
mechanisms of CD4+ T-cells are not fully understood. 
The CD4+ T-cells have no cytotoxic or cytolytic 
effects. Many cytokines produced by CD4+ T-cells are 
needed for the development of CD8+ effector cells. 
Tumor necrosis factor (TNF) and interferon-gamma 
(IFN-gamma) secreted by activated CD4+ T cells 
will induce expression of major histocompatibility 
complex I (MHC I) and induce CD8+ T-cell 
activity to lyse tumor cells.6-10 The induction phase 
of chemotherapy is usually used as a measure of 
successful chemotherapy, but remission failure rates 
are still high.10 Increased apoptosis of cancer cells 
induced by CD4+ or CD8+ T-cells can be used as 
one indicator of prognosis and response to induction 
phase chemotherapy in pediatric ALL patients.9 The 
aim of this study was to assess for correlations between 
apoptosis and CD4+, CD8+, and CD4+/CD8+ ratio, 
before and after the induction phase of chemotherapy 
in pediatric ALL patients. 
Methods
This observational, analytical, cohort study included 
25 new cases of pediatric ALL patients who were 
diagnosed based on bone marrow aspiration at the 
Department of Pediatrics, Airlangga University 
Medical School/Dr. Soetomo Hospital, Surabaya, from 
July to December 2016. The inclusion criteria were 
new cases of pediatric ALL aged 1 month to 16 years 
who had never received chemotherapy, and planned 
to undergo induction phase chemotherapy regularly 
for 6 weeks. The exclusion criteria were ALL patients 
with a history of HIV/AIDS or had infections as 
indicated by fever and other signs. Healthy patients 
control were obtained from healthy volunteers aged 1 
month to 16 years who had investigated no history of 
certain diseases and seem good condition during the 
examination was done.  This study was approved by 
the Ethics Committee of our institution and written 
informed consent was obtained from all patients’ 
parents.
Clinical characteristics including age, sex, 
hemoglobin (Hb) level, platelet count, and leukocyte 
count were obtained at diagnosis (before chemotherapy) 
and after induction phase chemotherapy. Whole blood 
(3 mL) with EDTA anticoagulant were used to measure 
absolute counts of CD4+, CD8+, and CD4+/CD8+ 
ratio. Reagents used for CD4+, CD8+ examination 
was  BD Multitest CD3FITC/CD8PE/CD45PerCP/
CD4APC. The principle of CD4+, CD8+examination 
was to detect bonds between antigens on the surface of 
the leukocyte present in the blood with fluorochrome 
labeled antibodies present in the reagents. Peripheral 
blood mononuclear cells (PBMC) were examined 
for apoptosis. The FITC Annexin V and propidium 
iodide (PI) were used for apoptosis examination. The 
principle of apoptosis examination was FITC Annexin 
V will bonds with phosphatidylserine that moves 
out of the cell when the cell undergoes apoptosis, 
then intercalation with propidium iodide (PI). The 
FITC Annexin V can identify early apoptosis, late 
apoptosis and necrosis based on nucleus changes. 
Propidium Iodide (PI) was used to distinguish late 
apoptosis and necrosis with early apoptosis. All 
examination were detected by flow cytometry BD 
FACSCalibur performed before and after induction 
phase chemotherapy, at the Department of Clinical 
Pathology, Airlangga University Medical School/ 
Dr. Soetomo Hospital, Surabaya.
Comparison of Hb levels before and after 
induction phase chemotherapy was evaluated by 
paired T-test, while leukocyte counts, platelet counts, 
CD4+, CD8+ cells, CD4+/CD8+ ratio, and apoptosis 
before and after induction phase chemotherapy were 
evaluated by Wilcoxon Signed Rank test. Correlations 
of absolute count of CD4+, CD8+ cells, CD4+/CD8+ 
ratio with apoptosis were evaluated by Spearman’s 
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correlation test. CD4+ -delta was defined as difference 
between number of CD4+ before and after induction 
phase chemotherapy, as well as CD8+-delta, CD4+/
CD8+-delta, and apoptosis delta. Results with P 
values ≤ 0.05 were considered to be statistically 
significant. 
  
Results
During the study period, 41 new cases of 
pediatric ALL patients fulfilled the inclusion criteria, 
but 16 patients dropped out, of whom 11 patients 
died and 5 patients did not complete the induction 
phase of chemotherapy. Hence, our cohort study of 
25 new cases of pediatric ALL patients consisted of 
16 males (64%) and 9 females (36%), with a 1.78:1 
ratio (Table 1). Many of our subjects were 3 years of 
age (20%). Leucocyte count was significantly lower 
(P=0.014) but platelet count was signigficantly higher 
(P=0.000), between before and after induction phase 
of chemotherapy. Mean numbers of CD4+ and CD8+ 
cells, as well as CD4+/CD8+ ratio were significantly 
decreased after induction phase chemotherapy. 
Mean numbers of CD4+ before induction phase 
chemotherapy was 3,060.24 (SD 4660.03), after 
induction phase chemotherapy was 887.64 (1531.33). 
Mean numbers of CD8+ before induction phase 
chemotherapy was 3,084.76 (SD 4535.51), after 
induction phase chemotherapy was 1,647.28 (SD 
3644.99). Mean numbers of CD4+/CD8+ ratio 
before induction phase chemotherapy was 1.12 (SD 
0.67), after induction phase chemotherapy was 0.65 
(SD 0.61). However, apoptosis did not significantly 
decrease after chemotherapy (P=0.689), before 
induction phase chemotherapy was 18.19 (SD 19.82) 
and after induction phase chemotherapy was 14.09 
(SD 10.85) (Table 2).  
Table 1. Clinical characteristics of study subjects before and after 
induction phase chemotherapy 
Characteristics N=25 P value
Gender, n
Male 
Female
16
  9
Age, n
1-5 years
6-10 years
≥ 10 years
13
  7
  5
Leucocyte count, x103 μL
Before
Mean (SD)
Median (range)
After
Mean (SD)
Median (range)
52.68  (120.45)
8.81 (1.20 – 585.00)
7.58 (10.78)
5.12 (0.79 – 56.00)
0.014*
Hb concentration, g/dL
Before
Mean (SD)
Median (range)
After
Mean (SD)
Median (range)
10.30 (3.13)
9.48 (5.00 – 16.00)
11.35 (2.02)
11.30 (7.60 – 15.40)
0.165
Thrombocyte count, x103 μL
Before
Mean (SD)
Median (range)
After
Mean (SD)
Median (range)
62.26 (54.17)
42.6 (5.00 – 204.00)
190.33 (119.07)
177.00 (18.80 – 447.00)
0.000*
*significant if P ≤ 0.05, Before=before induction phase chemotherapy, After=after induction 
phase chemotherapy
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A comparison of apoptosis was done in ALL 
patients and healthy control subjects. We found no 
significant differences in apoptosis between the two 
groups either before or after chemotherapy (Table 
3).   
We also assessed for correlations between 
apoptosis, before and after chemotherapy, and 
CD4+, CD8+ absolute counts, and CD4+/CD8+ 
ratio. There were significant, negative correlations 
between apoptosis and CD4+, as well as apoptosis and 
CD8+, before chemotherapy. However, there was no 
significant correlation between CD4+/CD8+ ratio and 
apoptosis, before or after chemotherapy (Table 4). 
There was a significant correlation between 
CD4+-delta and apoptosis-delta after induction phase 
chemotherapy. However, we observed no significant 
correlation between apoptosis-delta and CD8+-delta 
or CD4+/CD8+-delta (Table 5). 
Discussion
Acute lymphoblastic leukemia is a hematological 
malignancy that often occurs in children, and 
comprises 25–30% of all pediatric malignancies. 
The highest incidence is in 2–5-year-olds, and 
predominantly in boys. Our cohort study of 25 new 
cases of pediatric ALL patients consisted of 16 (64%) 
males and 9 (36%) females, with 1.78 : 1 ratio. Many 
subjects were 3 years of age (20%) (Table 1).
There were significant differences in leukocyte 
(P=0.014) and thrombocyte (P=0.000) counts, before 
and after induction phase chemotherapy. Uncontrolled 
lymphocyte proliferation and defective apoptosis 
in ALL patients caused leukocytosis dominated by 
lymphoblasts. Infiltration of hematopoetic cells by 
leukemic cells accumulated in the bone marrow 
Table 2. Comparison between CD4+, CD8+ cells, CD4+/CD8+ ratio, and apoptosis, before and after 
induction phase chemotherapy in pediatric ALL patients 
Variables Time Mean (SD) Median (range) P value
CD4+, cells Before
After
3,060.24 (4660.03)
887.64 (1531.33)
1751.00 (210.0 – 23,016.0
199.00 (4.0 – 5,966.0)
0.000*
CD8+, cells Before
After
3,084.76 (4535.51)
1,647.28 (3644.99)
1820.00 (341.0 – 18,541.0)
423.00 (52.0 – 17,859.0)
0.004*
CD4+/CD8+ ratio Before
After
1.12 (0.67)
0.65 (0.61)
1.03 (0.33 – 2.91)
0.44 (0.06 – 2.31)
0.004*
Apoptosis Before
After
18.19 (19.82)
14.09 (10.85)
10.83 (0.26 – 80.58)
10.34 (2.86 – 49.17)
0.689
*significant if P ≤ 0.05, Before=before induction phase chemotherapy, After=after induction phase chemotherapy
Table 3. Comparison of apoptosis between pediatric ALL patients and healthy children before 
and after induction phase chemotherapy 
Variables
Apoptosis
P value
Mean (SD) Median (range)
ALL patients (before chemotherapy)   18.19 (19.82) 10.83 (0.26-80.58) 0.683
Healthy control patients 16.21 (3.52) 17.73 (12.19-18.71)
ALL patients (after chemotherapy)   14.09 (10.85) 10.34 (2.86-49.17) 0.316
Healthy control patients 16.21 (3.52) 17.73 (12.19-18.71)
Table 4. Correlation between apoptosis and CD4+, CD8+ cells, and CD4+/CD8+ ratio before 
and after induction phase chemotherapy 
Variables
Correlation with apoptosis before 
chemotherapy
Correlation with apoptosis after 
chemotherapy
rs P value rs P value
CD4+ cells - 0.584 0.002   0.081 0.701
CD8+ cells - 0.556 0.004 - 0.105 0.619
CD4+/CD8+ ratio - 0.117 0.579   0.040 0.849
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causes anemia and thrombocytopenia.1,13 After 
chemotherapy, leukocyte count decreased, while Hb 
level and thrombocyte count increased. Evaluation 
of bone marrow aspiration after induction phase 
chemotherapy showed that all the patients were in 
remission, as determined by leukemic cell clearance 
from the bone marrow, mainly in the first 2 weeks after 
induction phase chemotherapy.13 
Mean CD4+, CD8+ cells, and CD4+/CD8+ 
ratio were significantly decreased after induction 
phase chemotherapy (Table 2). Verma et al. reported 
a significant decrease in B cells, T cells, and NK 
cells approximately 2 weeks after chemotherapy.14 
Decreased CD4+/CD8+ ratio after chemotherapy in 
this study (P=0.004) was due to the larger decrease 
in CD4+ cells than that in CD8+ cells. Recovery 
of CD4+ cells after chemotherapy was slower than 
recovery of CD8+ cells. Chemotherapy decreases 
the CD4+ and CD8+ cells by increasing regulatory 
T cells (T reg), which supress the immune response 
by downregulating IL-2, and upregulating IL-10 and 
TGF-beta. Although IL-10 and TGF-beta are strong, 
immunosupressive factors, IL-2 is an important 
immune regulating factor. It is produced by T helper 
cells, which increase T cell proliferation, NK cell 
activity, and B cell antibody secretion. Past studies 
have shown that IL-2 concentration in ALL patients 
is low.15,16  
After chemotherapy, apoptosis was not 
significantly decreased (P=0.689). In contrast, 
Laane et al. found an increase in apoptosis after 
chemotherapy.17 Firstly, our results may have been 
caused by: 1) sampling time outside the window of 
maximal effect on apoptosis time (24 - 72 hours). 
Liu et al. reported a significant increase in apoptosis 
of lymphoblasts > 24 hours after induction phase 
chemotherapy in pediatric ALL patients, rather than 
in the early hours after chemotherapy.18 Secondly, 
chemotherapy can cause necrosis, so lymphoblasts 
may not have been detected as apoptotic bodies.19 
Third, the subjects may have had chemotherapy 
drug resistance, although 100% of patients entered 
remission,20 and forth, anti-apoptotic proteins levels 
(e.g., BCL-2, BCL-XL, etc.) in the patients were higher 
than pro-apoptotic proteins levels (e.g., BAX, BOK, 
BCL-Xs, BID, BAD, or Noxa).18 Lymphoblast cells in 
ALL patients are more fragile than in healthy children, 
thus, apoptosis in ALL patients was not significantly 
higher than apoptosis in the healthy control group 
(Table 3).
There was a negative, significant correlation 
between apoptosis and CD4+ and CD8+ cells before 
chemotherapy (Table 4). This finding indicates that 
greater numbers of CD4+ and CD8+ cells result in 
decreased apoptosis. We noted that not only the 
number of CD4+ and CD8+ cells, but their function, 
was also important in immune response. The number 
and function of CD4+ and CD8+ cells before 
chemotherapy were correlated with subjects’ response 
to chemotherapy and improved survival.10 
Apoptosis had no significant correlation 
with CD4+/CD8+ ratio, either before or after 
chemotherapy. Similarly, Dewyer et al. suggested 
that CD4+/CD8+ ratio did not correlate with 
tumor response in induction phase chemotherapy.21 
No correlation between CD4+ or CD8+ cells and 
apoptosis after induction phase chemotherapy, may 
have been due to decreases of CD4+, CD8+ cells, 
and apoptosis after chemotherapy. 
There was a significant correlation between 
CD4+-delta (number of CD4+ cells before 
chemotherapy minus the number of CD4+ cells after 
chemotherapy) and apoptosis-delta (Table 5).  We 
found that decreased CD4+ cells lead to decreased 
apoptosis. The CD4+ cells had no cytotoxic or cytolytic 
effect on tumor cells, but many cytokines produced by 
CD4+ cells are needed for the development of CD8+ 
into effector cells.6-10
The limitations of this study included the lack of 
an extended time to recognize the possibility of future 
relapse or resistance to chemotherapy drugs, apoptosis 
sample preparation was not accompanied by a specific 
marker for lymphocytes, so a series of monocytes may 
have been included, and the sampling time among 
patients after chemotherapy varied, potentially 
effecting the decreased apoptosis.
Comparing the values before and after induction 
phase of chemotherapy we conclude that: 1) CD4+ 
and CD8+ count cells not significantly higher, 2) there 
is no difference in apoptosis, 3) there was a negative 
correlation between apoptosis and CD4+ and CD8+ 
cells before induction phase chemotherapy in pediatric 
ALL patients, but no correlation after induction 
phase chemotherapy, 4) there is no correlation 
between CD4+/CD8+ ratio and apoptosis, 5) there 
is a significant correlation between CD4+-delta and 
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apoptosis-delta, after induction phase chemotherapy. 
CD4+ and CD8+ cells, and CD4+/CD8+ ratio can 
be used to predict apoptosis before chemotherapy, 
while CD4+-delta may be useful to predict apoptosis 
after induction phase response to chemotherapy in 
ALL patients.
Suggestions for future research also include 
determining the best time of sampling after 
chemotherapy (24 hours, 36 hours, 48 hours, or 72 
hours) to obtain results with significantly increased 
apoptosis, compared to what our study showed, and 
to assess the profile of the percentage of T reg and 
expression of cytokines in ALL patients before and 
after chemotherapy.
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